Research Topics
| IGNACIO E SANZSummaryAffiliation: University of Rochester Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networksJennifer H Anolik
Department of Medicine, Division of Allergy, Immunology, and Rheumatology, University of Rochester, NY 14642, USA
J Immunol 180:688-92. 2008..This study provides initial evidence in humans to support the notion that anti-TNF treatment disrupts GC reactions at least in part via effects on follicular dendritic cells...
Decreased influenza-specific B cell responses in rheumatoid arthritis patients treated with anti-tumor necrosis factorJames J Kobie
Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
Arthritis Res Ther 13:R209. 2011..Therefore, we asked if short-term effector (d5-d10) and memory (1 month or later) B cell responses to antigen were compromised in RA patients treated with anti-TNF therapy...
B cells as therapeutic targets in SLEInaki Sanz
Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
Nat Rev Rheumatol 6:326-37. 2010..Combined, the available information identifies several new avenues for the therapeutic targeting of B cells in SLE...- Phenotypic and functional heterogeneity of human memory B cellsInaki Sanz
Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Semin Immunol 20:67-82. 2008.... - B cell depletion therapy in autoimmune diseasesInaki Sanz
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Front Biosci 12:2546-67. 2007..Finally, we will discuss some of the many challenges and opportunities that the medical and scientific community should address in the foreseeable future... - Reconstitution of the adult B cell repertoire after treatment with rituximabInaki Sanz
Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Arthritis Res Ther 7:175-6. 2005..The results presented by Rouzière and coworkers in their study of rheumatoid arthritis patients shed some light on this question and are discussed in this commentary... - A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosusChungwen Wei
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, NY 14642, USA
J Immunol 178:6624-33. 2007..These findings enhance our understanding of the B cell diversification pathways and provide mechanistic insight into the immunopathogenesis of SLE... - Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosusAmedeo Cappione
Department of Medicine, University of Rochester School of Medicine, Rochester, New York 14642, USA
J Clin Invest 115:3205-16. 2005..To our knowledge, this work represents the first comparative analysis of the fate of a specific autoreactive human B cell population. The results identify a defective tolerance checkpoint that appears to be specific for human SLE... - Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapyJennifer H Anolik
University of Rochester, Rochester, New York 14642, USA
Arthritis Rheum 56:3044-56. 2007..This study was undertaken to determine the magnitude, duration, and cause of these defects in rituximab-treated systemic lupus erythematosus (SLE) patients... - Expanded CD23(+)/CD21(hi) B cells in inflamed lymph nodes are associated with the onset of inflammatory-erosive arthritis in TNF-transgenic mice and are targets of anti-CD20 therapyJie Li
Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, NY 19642, USA
J Immunol 184:6142-50. 2010..On the basis of these findings, we propose a model whereby B cells contribute to arthritis in mice, and possibly RA, by directly affecting the structure, composition, and function of joint-draining lymph nodes... - Lupus IgG VH4.34 antibodies bind to a 220-kDa glycoform of CD45/B220 on the surface of human B lymphocytesAmedeo J Cappione
Department of Medicine, Clinical Immunology and Rheumatology Unit, University of Rochester Medical Center, Rochester, NY 14642, USA
J Immunol 172:4298-307. 2004..Overall, our data indicate that V(H)4.34 Abs represent a major component of the lupus IgG autoantibody repertoire and suggest that the carbohydrate moiety they recognize may act as a selecting Ag in SLE... - Altered B cell receptor signaling in human systemic lupus erythematosusScott A Jenks
Department of Medicine, Division of Allergy, Immunology and Rheumatology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, New York 14642, USA
Autoimmun Rev 8:209-13. 2009..Intracellular flow cytometric analysis of signaling is a useful approach to accomplish this goal... - B cell depletion therapy in systemic lupus erythematosusJennifer Anolik
Department of Medicine Immunology and Rheumatology, University of Rochester School of Medicine, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
Curr Rheumatol Rep 5:350-6. 2003..Recent open-label studies indicate that rituximab is safe and may be efficacious in the treatment of SLE, and continued study with randomized clinical trials is justified... - Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adultsF Eun Hyung Lee
Division of Pulmonary and Critical Care Medicine, University of Rochester and Rochester General Hospital, Rochester, New York, USA
J Infect Dis 202:1659-66. 2010..The specificity and duration of circulating human antibody-secreting cells (ASCs) after vaccination have been well described, but characteristics of ASCs during acute respiratory infections have not been well studied... - Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosusJennifer H Anolik
University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14642, USA
Arthritis Rheum 50:3580-90. 2004.... - Down-regulation of CD20 on B cells upon CD40 activationJennifer Anolik
Department of Medicine, University of Rochester School of Medicine, Rochester 14642, USA
Eur J Immunol 33:2398-409. 2003.... - Treatment of SLE with anti-CD20 monoclonal antibodyR John Looney
Allergy Immunology, Rheumatology Unit, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Curr Dir Autoimmun 8:193-205. 2005..This article will review the role of B cells in human SLE as well as the currently available data on the treatment of SLE by depleting B cells with anti-CD20 (rituximab)... - B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximabR John Looney
University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
Arthritis Rheum 50:2580-9. 2004..B lymphocytes have been shown to play fundamental pathogenic roles in SLE, and therefore, elimination of B cells with the use of rituximab may represent a new therapy for SLE... - New therapies for systemic lupus erythematosus: cellular targetsR John Looney
Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY14420, USA
Rheum Dis Clin North Am 32:201-15, xi. 2006..This article discusses the B-cell abnormalities found in systemic lupus erythematosus and the clinical and immunologic effects of anti-B-cell therapies... - B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogenyJennifer H Anolik
Department of Medicine, Division of Clinical Immunology and Rheumatology, James P Wilmot Cancer Center, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
Clin Immunol 122:139-45. 2007..0001). Expansion of functionally immature B cells and decreased memory B cells may contribute to an immunodeficient state in patients recovering from rituximab mediated B cell depletion, particularly with repeated treatment... - Novel human transitional B cell populations revealed by B cell depletion therapyArumugam Palanichamy
Department of Medicine, Division of Clinical Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY 14642, USA
J Immunol 182:5982-93. 2009..The characterization of multiple transitional B cell subpopulations provides important insights into human B cell development... - Human innate B cells: a link between host defense and autoimmunity?Eric C B Milner
Department of Medicine, Clinical Immunology and Rheumatology Unit, University of Rochester Medical School, 601 Elmwood Avenue, Box 695, Rochester, NY 14642, USA
Springer Semin Immunopathol 26:433-52. 2005.... - B cells in human and murine systemic lupus erythematosusJennifer Anolik
Department of Medicine, Clinical Immunology and Rheumatology Unit, Rochester, New York 14642, USA
Curr Opin Rheumatol 16:505-12. 2004.... - B cells and immunological toleranceNataly Manjarrez-Orduno
Division of Allergy, Immunology and Rheumatology, Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
J Invest Dermatol 129:278-88. 2009.... - Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?Ismael Calero
Department of Internal Medicine, Hospital Virgen de la Luz, Cuenca, Spain
Discov Med 10:416-24. 2010..These models could also help frame the design and evaluation of current and future B cell therapies...
Research Grants
- Identification of Biomarkers in Sjogren's SyndromeIGNACIO E SANZ; Fiscal Year: 2010....
- Understanding the Generation of HIV Broadly Neutralizing AntibodiesIGNACIO E SANZ; Fiscal Year: 2010..We propose to precisely identify the B cells that produce protective HIV neutralizing antibodies in order to determine how they arise, are maintained, and how vaccines can be modeled to induce them. ..
- Suppression and Exacerbation of B and T cell Responses *Ignacio Sanz; Fiscal Year: 2007..abstract_text> ..
- Identification of Biomarkers in Sjogren's SyndromeIgnacio Sanz; Fiscal Year: 2007....
- A Model System for the Study of Human B-cell ToleranceIgnacio Sanz; Fiscal Year: 2007..Furthermore, we believe that our results will improve our ability to treat patients with SLE and similar diseases. ..
- Study of Human B-cell Tolerance by Functional GenomicsIgnacio Sanz; Fiscal Year: 2005..In addition, although the questions asked are hypothesis-driven, the approach proposed is highly exploratory and, as such, is responsive to this RFA. ..
- Understanding the Generation of HIV Broadly Neutralizing AntibodiesIGNACIO E SANZ; Fiscal Year: 2010..We propose to precisely identify the B cells that produce protective HIV neutralizing antibodies in order to determine how they arise, are maintained, and how vaccines can be modeled to induce them. ..